The Food and Drug Administration's approval of aripiprazole for the acute treatment of bipolar I disorder in children and adolescents is helpful for physicians and parents, according to an investigator in the study that led to the approval.
The FDA has approved the atypical antipsychotic aripiprazole (Abilify) for treatment of manic and mixed episodes associated with bipolar I disorder in children and adolescents.
"When parents have questions now, they can now look to the indication and the labeling to know what the common side effects are, how long it takes for the medicine to work, and what they can expect," Dr. Adelaide Robb, medical director of inpatient ...